---

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

---

 

FORM 8-K

 

---

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report  (Date of earliest event reported):     June 3, 2004

 

---

 

BioMarin Pharmaceutical Inc.

(Exact name of registrant as specified in its charter)

 

---

 

Delaware		000-26727		68-0397820
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(IRS Employer Identification No.)

 

371 Bel Marin Keys Boulevard, Suite 210, Novato, California		94949
(Address of principal executive offices)		(Zip Code)

 

Registrant’s telephone number, including area code:      (415) 506-6700

 

Not Applicable

(Former name or former address, if changed since last report)

 

---

 

Item 5. Other Events.

 

On June 3, 2004, BioMarin Pharmaceutical Inc. (the “Registrant”), issued a press release regarding the announcement of the data and results of its Phase 3 trial of Aryplase™ for the treatment of MPS VI. The Registrant’s press release issued on June 3, 2004 is attached hereto as Exhibit 99.1.

Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits.

 

(a)

Financial Statements of Business Acquired.

 

Not Applicable.

 

(b)

Pro Forma Financial Information.

 

Not Applicable.

 

(c)

Exhibits.

 

Exhibit 99.1		Press Release of the Registrant dated June 3, 2004.

---

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

		BioMarin Pharmaceutical Inc., a Delaware corporation
Date: June 3, 2004	By:	/s/ Louis Drapeau
		Louis Drapeau Chief Financial Officer

---

EXHIBIT INDEX

 

Exhibit No.		Description
Exhibit 99.1		Press Release of the Registrant dated June 3, 2004